Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. (Nasdaq: LFWD) is a medical device company that focuses on technologies for physical rehabilitation and recovery, including the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System. This news page aggregates company press releases and third-party coverage so readers can follow how Lifeward’s business and strategy develop over time.
Recent news highlights Lifeward’s progress in reimbursement and market access for its ReWalk 7 Personal Exoskeleton. The company has reported prior authorization approvals and payments from Medicare Advantage plans, including UnitedHealthcare and a Humana Medicare Advantage Plan, following the establishment of a formal Medicare reimbursement pathway for personal exoskeletons by CMS. These updates provide insight into payer adoption trends and Lifeward’s efforts to support access for individuals with spinal cord injury.
Lifeward’s news flow also covers international expansion and regulatory milestones. The company announced CE mark approval for the ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe, and a distribution agreement with Verita Neuro to offer ReWalk in Mexico, Thailand, and the United Arab Emirates. These items help investors and clinicians understand how Lifeward is extending its commercial footprint beyond its core markets in the United States, Israel, and Germany.
Another important theme in Lifeward’s news is its strategic partnership with Oramed Pharmaceuticals. The parties have agreed to transfer Oramed’s Protein Oral Delivery (POD™) technology to Lifeward, with Oramed becoming a significant shareholder and managing the clinical program. Coverage of this transaction explains how Lifeward aims to operate as a biomedical portfolio company that combines revenue-generating MedTech products with longer-term biotech opportunities.
Visitors can use this page to review updates on financial results, capital raises, board and management changes, regulatory approvals, reimbursement developments, and strategic transactions involving LFWD.
Lifeward (NASDAQ: LFWD), a leader in medical technology for people with physical limitations, has announced its participation in the upcoming Sidoti May Virtual Investor Conference. CEO Larry Jasinski and CFO Mike Lawless will represent the company, delivering a corporate presentation on May 21, 2025, at 10:00 AM EDT.
The executives will also host one-on-one meetings with investors during the two-day conference on May 21-22, 2025. Investors can access the presentation through a provided Zoom link and register for both the presentation and one-on-one meetings through the Sidoti website. Registration is complimentary and open to all interested investors, regardless of Sidoti client status.
Lifeward (Nasdaq: LFWD), a global leader in medical technology for people with physical limitations or disabilities, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. CEO Larry Jasinski and CFO Mike Lawless will host a conference call and webcast at 8:30 a.m. EDT to discuss the results.
The earnings call will be accessible via multiple toll-free numbers across the U.S., Germany, and Israel. Investors can also access the webcast through the company's website at GoLifeward.com in the "Investors" section, with an archived version available afterward.
Lifeward announced a significant milestone as the first major U.S. commercial health insurer approves coverage for the ReWalk 7 Personal Exoskeleton. This breakthrough follows the device's U.S. sales launch in April 2025 and its FDA clearance in March 2025.
The ReWalk 7 enables individuals with spinal cord injury (SCI) to stand, walk, and navigate stairs in everyday environments. This approval builds on the 2024 Medicare reimbursement pathway established by CMS, which covers approximately one-third of SCI individuals nationwide.
CEO Larry Jasinski emphasized this development as crucial for market expansion, noting that commercial insurers cover a significant portion of SCI individuals. The company views this approval as momentum for engaging more commercial insurers and strengthening growth prospects.
Lifeward (Nasdaq: LFWD) announced that a paralyzed Israeli soldier has successfully completed training and received a ReWalk Personal Exoskeleton, becoming the first Israeli war casualty to regain walking ability through this technology. The 25-year-old reserve combat soldier from the IDF Paratroopers Reserve Brigade, who suffered paralysis in both legs, underwent rehabilitation at Beilinson Hospital under Dr. Yaron Watts's supervision.
Dr. Watts described this as a 'precedent-setting historic event' and advocated for the system's recognition by the Rehabilitation Department of the Ministry of Defense, similar to smart prosthetics provided to amputees. The Israeli Rehabilitation Department is now evaluating the device's safety and effectiveness for other paralyzed Veterans following this successful case.
Lifeward (NASDAQ: LFWD) has launched the ReWalk 7 Personal Exoskeleton in the U.S. market, following FDA clearance in March 2025. This seventh-generation exoskeleton for individuals with spinal cord injury (SCI) features significant improvements including:
- Customizable walking speeds for indoor/outdoor environments
- Crutch Control system for enhanced user control
- Wrist Control smartwatch and MyReWalk mobile app integration
- Improved battery life and seamless stairs/curbs navigation
- New therapist handheld device for training
The development involved extensive testing with dozens of end users and physical therapists. This launch follows two major milestones: the 2023 addition of stairs and curbs navigation capability to ReWalk 6.0, and the 2024 establishment of a Medicare reimbursement pathway by CMS for personal exoskeletons.
Lifeward (Nasdaq: LFWD) has received FDA 510(k) clearance for its ReWalk 7, the newest generation of its personal exoskeleton device designed for individuals with spinal cord injury (SCI). This seventh-generation wearable exoskeleton enables SCI patients to stand and walk again, featuring new enhancements and upgrades.
This milestone follows significant developments including the 2023 FDA clearance of ReWalk 6.0 for stairs and curbs usage, and the 2024 Centers for Medicare & Medicaid Services (CMS) national reimbursement policy approval for qualified beneficiaries. The company, which made history in 2014 with the first FDA-cleared exoskeleton medical device for SCI patients, will commence ReWalk 7 sales in the United States once the product becomes available.
Lifeward (NASDAQ: LFWD) reported strong financial results for Q4 and full year 2024, achieving record revenue of $7.5M for Q4 and $25.7M annually, representing an 85% year-over-year growth. ReWalk Personal Exoskeleton sales surged 130% in 2024, driven by Medicare coverage.
Q4 2024 highlights include: gross margin of 24.4% (45.4% non-GAAP), operating loss of $15.2M ($3.3M non-GAAP), and net loss of $15.3M ($1.73 per share). The company ended 2024 with $6.7M in cash and no debt, supplemented by a $5.0M registered direct offering in January 2025.
For 2025 guidance, Lifeward projects revenue of $28-30M, adjusted gross margins of 47-49%, and expects to reduce non-GAAP operating loss to approximately $1M by Q4 2025 through its Sustainable Growth Plan focusing on core product lines and streamlined operations.